1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
United Therapeutics Corporation

United Therapeutics Corporation

UTHR
United Therapeutics CorporationUS flagNASDAQ Global Select
499.73
USD
-1.54
- -
21.21BMarket Cap
United Therapeutics Corporation
UTHR
(NASDAQ Global Select)

Recent

price

499.73

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
10.56
13
17.59
22.31
26.75
31.87
36.5
39.21
37.42
33.08
33.56
37.54
42.56
49.73
63.66
71.84
72.85
Revenue per Share
1.89
3.81
5.84
3.49
7.06
14.17
16.29
9.5
13.54
-2.39
11.65
10.6
15.98
21.04
26.44
30.13
30.27
Basic EPS, GAAP
3.44
3.75
4.06
7.86
6.39
7.24
13.71
8.82
13.66
-6.63
15.76
10.63
14.59
15.97
23.91
23.37
25.24
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
15.36
17.69
21.61
24.99
26.37
34.72
43.09
48.61
63.98
63.36
76.28
87.77
104.2
127.23
143.74
162.6
149.97
Book Value per Share
15.19
17.28
21.28
24.71
25.75
34.09
42.3
47.55
60.06
59.75
72.73
86.78
103.24
124.8
141.24
159.93
147.3
Tangible Book Value per Share
56
57
52
50
48
46
44
44
44
44
44
45
46
47
45
44
43
Basic Weighted Avg Shares
593
743
916
1,117
1,288
1,466
1,599
1,725
1,628
1,449
1,483
1,686
1,936
2,328
2,877
3,183
3,154
Sales/Revenue/Turnover
28.89
42.76
46.03
26.19
41.82
47.69
66.41
59.4
49.48
-12.95
40.02
32.98
50.6
50.91
50.33
47.67
44.49
Operating Margin (%)
18
21
27
31
32
33
32
31
36
46
50
50
51
53
72
86
92
Depreciation Expense
106
218
304
175
340
652
714
418
589
-104
515
476
727
985
1,195
1,335
1,311
Net Income, GAAP
28.32
27.37
30.91
37.41
35.24
37.61
32.68
45.69
22.36
- -
19.42
19.89
23.49
22.72
22.35
22.12
16.66
Effective Tax Rate (%)
17.86
29.32
33.23
15.63
26.4
44.45
44.64
24.22
36.2
-7.21
34.71
28.23
37.56
42.31
41.53
41.94
41.56
Profit Margin (%)
336
350
492
227
453
835
1,092
1,003
1,491
1,402
1,844
2,018
3,037
2,747
3,136
3,142
2,876
Working Capital
69
266
275
4
- -
- -
- -
250
250
600
800
800
800
300
- -
- -
- -
LT Debt
884
959
1,095
1,304
1,266
1,600
1,862
2,121
2,808
2,780
3,395
3,959
4,797
5,985
6,444
7,096
6,400
Total Equity
11.74
19.12
22.44
12.36
23.4
29.1
41.23
26.3
23.04
- -
12.22
9.95
14.48
14.91
16.75
17.07
17.23
Return on Invested Capital (%)
11.47
19.34
24.34
12.55
23.57
43.68
41.32
19.97
22.1
- -
13.64
10.96
14.53
16.78
18.3
19.51
19.46
Return on Capital (%)
13.78
23.78
29.96
14.9
27.19
46.03
41.5
21.14
24.1
-3.75
16.67
12.94
16.61
18.27
19.23
19.71
19.32
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
44
42
43
Market Capitalization
21,265
24,998
23,124

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
3,702
2,872
3,484
Cash, Cash Equivalents & STI
2,920
2,154
2,662
Accounts Receivable, Net
350
312
310
Inventories
183
178
194
Total Current Liabilities
561
599
608
Payables & Accruals
488
498
498
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
16.41%
16.06%
10.12%
Free Cash Flow
-33.02%
12.11%
-4.2%
Net Income, GAAP
-58.76%
22.74%
11.68%
Sales/Revenue/Turnover
8.57%
16.59%
10.61%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
678
715
749
736
2,877
2025
794
799
800
790
3,183
2026
782
783
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
6.52
6.26
6.93
6.74
26.44
2025
7.18
6.86
7.73
8.41
30.13
2026
6.32
7.82
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Cell Source, Inc. (CLCS)
MoonLake Immunotherapeutics (MLTX)
Shanghai Bao Pharmaceuticals Co., Ltd. (2659.HK)
Arecor Therapeutics plc (AREC.L)
Hoth Therapeutics, Inc. (HOTH)
Silexion Therapeutics Ltd. (SLXNW)
Business
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit biotechnology company founded in 1996 and headquartered in Silver Spring, Maryland, with co-headquarters in Research Triangle Park, North Carolina, develops and commercializes innovative products to address unmet medical needs of patients with chronic and life-threatening diseases, particularly pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF), high-risk neuroblastoma, and organ failure; its core commercial portfolio includes Tyvaso DPI and Tyvaso, inhaled formulations of treprostinil via dry powder inhaler and nebulizer for PAH and other lung conditions; Remodulin (treprostinil) injection and Orenitram (treprostinil extended-release tablets) for PAH to improve exercise capacity and delay disease progression; Adcirca (tadalafil), an oral PDE-5 inhibitor for PAH; Unituxin (dinutuximab) injection, a monoclonal antibody for pediatric high-risk neuroblastoma; and Remunity Pump, a subcutaneous delivery system for Remodulin. The company operates in the United States, Canada, Central and South America, Europe, the Middle East, and Asia through distribution partners and maintains manufacturing facilities in locations including Melbourne and Jacksonville, Florida; Blacksburg, Virginia; Manchester, New Hampshire; and Magog and Bromont, Quebec. United Therapeutics targets patients with cardiovascular, pulmonary, oncology, and organ transplant needs, while advancing a pipeline featuring RemoPro and ralinepag for PAH, Aurora-GT gene therapy for lung vascular rebuilding, nebulized Tyvaso for IPF, and xenotransplantation technologies including UKidney for end-stage renal disease via xenografts, allogenic recellularization, and bioprinting. In recent developments, United Therapeutics announced the first human transplant in its EXPAND clinical trial of UKidney for end-stage renal disease in November 2025, marking a milestone in xenotransplantation; the company reported positive top-line results from the phase 3 TETON-2 pivotal study of nebulized Tyvaso in IPF in September 2025, meeting the primary endpoint and key secondary measures across subgroups; it initiated a $1 billion accelerated share repurchase program in August 2025 with Citibank to return capital to shareholders while supporting growth; and earlier acquired IVEVA and MiroMatrix to bolster organ manufacturing expertise, alongside investments in new manufacturing facilities and designated pathogen-free sites.

Company News

APIChatGPT

  • defenseworld.net

    United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

  • defenseworld.net

    Atwood & Palmer Inc. Sells 957 Shares of United Therapeutics Corporation $UTHR

  • zacks.com

    United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark

  • marketbeat.com

    United Therapeutics Q2 Earnings Call Highlights

  • seekingalpha.com

    United Therapeutics Corporation (UTHR) Q2 2026 Earnings Call Transcript

  • zacks.com

    United Therapeutics (UTHR) Reports Q2 Earnings: What Key Metrics Have to Say

  • zacks.com

    United Therapeutics (UTHR) Q2 Earnings Surpass Estimates

  • businesswire.com

    United Therapeutics Corporation Reports Second Quarter 2026 Financial Results

  • zacks.com

    UTHR or SDZNY: Which Is the Better Value Stock Right Now?

  • businesswire.com

    United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet

  • fool.com

    United Therapeutics CEO Sells $5 Million of Shares. What Does This Mean for Investors?

  • zacks.com

    Liquidia vs. United Therapeutics: Which PAH Stock Is the Better Buy Now?

  • defenseworld.net

    Atika Capital Management LLC Invests $7.32 Million in United Therapeutics Corporation $UTHR

  • gurufocus.com

    United Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors

  • businesswire.com

    United Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors

  • businesswire.com

    United Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026

  • fool.com

    PINK vs. IXJ: Which Health Care ETF Is the Better Buy for Investors?

  • defenseworld.net

    California Public Employees Retirement System Grows Stock Holdings in United Therapeutics Corporation $UTHR

  • zacks.com

    United Therapeutics Stock Rises 14% YTD: Here's What You Need to Know

  • seekingalpha.com

    United Therapeutics: Trifecta Of 2026 Tyvaso Franchise Filings Makes It A Compelling Buy